Partnering Manufacturing Strategies & Facility Design For Patient-Centric Medicine Delivery

Manufacturing therapeutic recombinant proteins from mammalian cell culture presents unique challenges. Traditional strategies like scale-up, scale-out, and continuous manufacturing are suited for different supply scenarios, but transitioning between them often requires significant investment and time.

Our kojoX™ platform offers a modular approach to manufacturing, addressing these challenges, and ensuring a robust supply chain for medicines. By standardizing process design, validation, and operation, kojoX™ de-risks the production process, from pre-clinical to commercial scale.

Key Learning Objectives:

• Navigating Supply Chain Challenges: Understand the impact of global supply chain disruptions and rising costs on biologics manufacturing.
• Optimizing Production Strategies: Evaluate different production strategies to meet the evolving demands of the market for rapid and cost-effective therapy delivery.
• Accelerating Time to Market: Learn how standardized, modular process designs can reduce risks and enhance scalability, from early-stage development to large-scale manufacturing.

This presentation delves into the importance of selecting the most suitable manufacturing strategy and how kojoX, combined with our ApolloX technology, can streamline the process from cell line development to commercial production at 20K L scale.